Apex Biotechnology Corp Stock Working Capital
| 1733 Stock | TWD 28.50 0.15 0.53% |
Apex Biotechnology Corp fundamentals help investors to digest information that contributes to Apex Biotechnology's financial success or failures. It also enables traders to predict the movement of Apex Stock. The fundamental analysis module provides a way to measure Apex Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Apex Biotechnology stock.
Apex |
Apex Biotechnology Corp Company Working Capital Analysis
Apex Biotechnology's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Apex Biotechnology Working Capital | 1.12 B |
Most of Apex Biotechnology's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Apex Biotechnology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, Apex Biotechnology Corp has a Working Capital of 1.12 B. This is 163.36% higher than that of the Health Care Equipment & Supplies sector and 108.13% higher than that of the Health Care industry. The working capital for all Taiwan stocks is 24.16% higher than that of the company.
Apex Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apex Biotechnology's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apex Biotechnology could also be used in its relative valuation, which is a method of valuing Apex Biotechnology by comparing valuation metrics of similar companies.Apex Biotechnology is currently under evaluation in working capital category among its peers.
Apex Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0434 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 2.45 B | |||
| Shares Outstanding | 99.95 M | |||
| Shares Owned By Insiders | 15.50 % | |||
| Shares Owned By Institutions | 2.52 % | |||
| Price To Earning | 31.02 X | |||
| Price To Book | 1.46 X | |||
| Price To Sales | 1.12 X | |||
| Revenue | 2.13 B | |||
| Gross Profit | 571.51 M | |||
| EBITDA | 293.14 M | |||
| Net Income | 202.22 M | |||
| Cash And Equivalents | 523.23 M | |||
| Cash Per Share | 5.25 X | |||
| Total Debt | 526.89 M | |||
| Debt To Equity | 31.40 % | |||
| Current Ratio | 3.21 X | |||
| Book Value Per Share | 17.73 X | |||
| Cash Flow From Operations | 179.87 M | |||
| Earnings Per Share | 2.17 X | |||
| Target Price | 76.45 | |||
| Number Of Employees | 17 | |||
| Beta | 0.36 | |||
| Market Capitalization | 2.57 B | |||
| Total Asset | 2.67 B | |||
| Retained Earnings | 617 M | |||
| Working Capital | 1.12 B | |||
| Current Asset | 1.76 B | |||
| Current Liabilities | 638 M | |||
| Z Score | 2.4 | |||
| Annual Yield | 0.05 % | |||
| Five Year Return | 4.55 % | |||
| Net Asset | 2.67 B | |||
| Last Dividend Paid | 1.3 |
About Apex Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apex Biotechnology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apex Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apex Biotechnology Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Apex Stock Analysis
When running Apex Biotechnology's price analysis, check to measure Apex Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apex Biotechnology is operating at the current time. Most of Apex Biotechnology's value examination focuses on studying past and present price action to predict the probability of Apex Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apex Biotechnology's price. Additionally, you may evaluate how the addition of Apex Biotechnology to your portfolios can decrease your overall portfolio volatility.